Suppr超能文献

加拿大使用经皮微轴心室辅助装置治疗儿童心源性休克的经验。

A Canadian Experience With a Percutaneous Microaxial Ventricular Assist Device in Children With Cardiogenic Shock.

作者信息

Langanecha Bhavikkumar D, Power Alyssa, Vanderlaan Rachel D, Honjo Osami, Zaulan Oshri, Maurich Andrea, Chaturvedi Rajiv, Jeewa Aamir

机构信息

Labatt Family Heart Centre, Division of Pediatric Cardiology, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada.

Division of Critical Care Medicine, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada.

出版信息

CJC Pediatr Congenit Heart Dis. 2025 Feb 6;4(3):160-169. doi: 10.1016/j.cjcpc.2025.01.004. eCollection 2025 Jun.

Abstract

BACKGROUND

The experience of a percutaneous microaxial (Impella) left ventricular assist device in children with cardiogenic shock is limited. The primary objective of this study was to review our institutional clinical outcomes of Impella use in children with cardiogenic shock.

METHODS

This is a single-center retrospective study of all adult-sized children who underwent Impella implantation from June 2019 to December 2024. Clinical outcomes, hemodynamics, and device complication data were collected.

RESULTS

A total of 7 patients (female = 4) with a median (interquartile range [IQR]) age of 15 years (14.5, 16.5 years) and a median weight of 50.9 kg (46.5, 59.85 kg) underwent Impella insertion during the study period. Five patients underwent Impella insertion for hemodynamic support and 2 for left ventricular decompression while on extracorporeal membrane oxygenation (ECMO) support. The underlying cardiac diagnoses were dilated cardiomyopathy (4 of 7), myocarditis (2 of 6), and hypertrophic cardiomyopathy with presumed myocarditis (1 of 7). The median (IQR) duration of support was 5 days (2, 7 days). The median (IQR) duration of intensive care unit and hospital stay was 13 days (10.5, 19 days) and 23 days (15, 54 days), respectively. Three patients were ultimately bridged to a durable ventricular assist device, and 2 patients had recovery of myocardial function. One patient developed significant aortic regurgitation, which necessitated device explantation and conversion to central ECMO after 38 hours of support, and one patient had withdrawal of life-sustaining measures due to significant brain injury unrelated to Impella.

CONCLUSIONS

There is increasing use of percutaneous microaxial pumps for supporting children in cardiogenic shock and left ventricle decompression on ECMO support. This report identifies the initial Canadian experience as an addition to the mechanical circulatory support armamentarium.

摘要

背景

经皮微轴(Impella)左心室辅助装置在儿童心源性休克中的应用经验有限。本研究的主要目的是回顾我们机构使用Impella治疗儿童心源性休克的临床结果。

方法

这是一项对2019年6月至2024年12月期间接受Impella植入的所有成年体型儿童进行的单中心回顾性研究。收集了临床结果、血流动力学和装置并发症数据。

结果

在研究期间,共有7例患者(女性4例)接受了Impella植入,中位(四分位间距[IQR])年龄为15岁(14.5,16.5岁),中位体重为50.9 kg(46.5,59.85 kg)。5例患者接受Impella植入以获得血流动力学支持,2例在体外膜肺氧合(ECMO)支持下接受Impella植入以进行左心室减压。潜在的心脏诊断为扩张型心肌病(7例中的4例)、心肌炎(6例中的2例)和疑似心肌炎的肥厚型心肌病(7例中的1例)。中位(IQR)支持时间为5天(2,7天)。重症监护病房和住院的中位(IQR)时间分别为13天(10.5,19天)和23天(15,54天)。3例患者最终过渡到持久的心室辅助装置,2例患者心肌功能恢复。1例患者出现严重主动脉瓣反流,在支持38小时后需要取出装置并转换为中心ECMO,1例患者因与Impella无关的严重脑损伤而停止维持生命的措施。

结论

经皮微轴泵在支持心源性休克儿童和ECMO支持下的左心室减压方面的应用越来越多。本报告确定了加拿大的初步经验,作为机械循环支持手段的补充。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08f4/12418258/f03188d607d9/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验